Literature DB >> 14967961

Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?

Jeffrey L Anderson1, Benjamin D Horne, Heath U Jones, Sandra P Reyna, John F Carlquist, Tami L Bair, Robert R Pearson, Donald L Lappé, Joseph B Muhlestein.   

Abstract

BACKGROUND: The prevalence of the metabolic syndrome (MS) is growing. The Adult Treatment Panel (ATP) III provided a uniform definition of MS but no information on its predictive ability.
METHODS: We tested the ability of MS and its components to predict angiographic coronary artery disease (CAD) and incident death/myocardial infarction (D/MI) over 2.8 +/- 2.3 years in a large cohort of patients undergoing angiography. ATP-III criteria were used for fasting glucose (FG), triglyceride (TG), high-density lipoprotein cholesterol (HDL), and blood pressure (BP); body mass index (BMI) >27 kg/m(2) was used as a surrogate for waist circumference.
RESULTS: 3,128 subjects were studied; 65% had advanced CAD (>/=70% stenosis), and 35%, no CAD. MS was present in 64% (high FG 40%; high TG 52%; low HDL 71%; high BP 76%; high BMI 58%). Presence of CAD was predicted by MS [adjusted odds ratio (OR) = 1.30, 95% CI 1.10-1.55, p = 0.003] and, individually, by high FG (OR = 1.90, CI 1.63-2.23) and low HDL (OR = 1.38, CI 1.18-1.62). In multivariable modeling, CAD was predicted by high FG (OR = 1.80, CI 1.51-2.16) and low HDL (OR = 1.57, CI 1.31-1.89) as well as by age, gender, family history, smoking, and LDL cholesterol (all p < 0.001). For secondary risk of incident D/MI, only high FG of MS features was predictive (adjusted hazard ratio 1.46, CI 1.17-1.82, p = 0.001), and this risk was carried by diabetes (adjusted hazard ratio 1.71, p < 0.001); other predictors were age, heart failure, revascularization strategy, renal insufficiency, prior MI, and number of diseased vessels.
CONCLUSION: MS has primary predictive ability for CAD, carried primarily by high FG and low HDL. Secondary predictive ability of MS features for clinical outcomes, in the setting of established CAD, is carried by diabetes alone. Dysglycemia deserves specific attention as a target for prevention and treatment. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967961     DOI: 10.1159/000076695

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  9 in total

Review 1.  Treatment of the metabolic syndrome: the impact of lifestyle modification.

Authors:  Allison M Pritchett; John P Foreyt; Douglas L Mann
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 2.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

3.  Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome.

Authors:  Angel Lopez-Candales; Paula M Hernández Burgos; Dagmar F Hernandez-Suarez; David Harris
Journal:  J Nat Sci       Date:  2017-04

4.  Comparison of components of metabolic syndrome in premature myocardial infarction in an Iranian population: a case -control study.

Authors:  Toba Kazemi; Gholamreza Sharifzadeh; Asghar Zarban; Azita Fesharakinia
Journal:  Int J Prev Med       Date:  2013-01

5.  Linkage of epidemiologic evidence with the clinical aspects of metabolic syndrome.

Authors:  Sun Ha Jee; Jaeseong Jo
Journal:  Korean Circ J       Date:  2012-06-28       Impact factor: 3.243

6.  A comparison of predictability of cardiovascular events between each metabolic component in patients with metabolic syndrome based on the revised National Cholesterol Education Program criteria.

Authors:  In-Cheol Hwang; Kyoung-Kon Kim; Sun-Ha Jee; Hee-Cheol Kang
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

Review 7.  Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.

Authors:  Alexander Tenenbaum; Robert Klempfner; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2014-12-04       Impact factor: 9.951

8.  Metabolic Syndrome and Coronary Artery Disease Risk: A Meta-Analysis of Observational Studies.

Authors:  Amal F Alshammary; Khalid Khalaf Alharbi; Naif Jameel Alshehri; Vishal Vennu; Imran Ali Khan
Journal:  Int J Environ Res Public Health       Date:  2021-02-11       Impact factor: 3.390

9.  Impact of Metabolic Syndrome and It's Components on Prognosis in Patients With Cardiovascular Diseases: A Meta-Analysis.

Authors:  Xiao Li; Yajing Zhai; Jiaguo Zhao; Hairong He; Yuanjie Li; Yue Liu; Aozi Feng; Li Li; Tao Huang; Anding Xu; Jun Lyu
Journal:  Front Cardiovasc Med       Date:  2021-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.